K
Kenneth M. Kral
Researcher at Research Triangle Park
Publications - 19
Citations - 2751
Kenneth M. Kral is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Fluticasone propionate & Fluticasone. The author has an hindex of 13, co-authored 19 publications receiving 2662 citations. Previous affiliations of Kenneth M. Kral include GlaxoSmithKline.
Papers
More filters
Journal ArticleDOI
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.
David B. Badesch,Victor F. Tapson,Michael D. McGoon,Bruce H. Brundage,Lewis J. Rubin,Fredrick M. Wigley,Stuart Rich,Robyn J. Barst,Pamela S. Barrett,Kenneth M. Kral,Maria M. Jöbsis,James E. Loyd,Srinivas Murali,Adaani E. Frost,Reda E. Girgis,Robert C. Bourge,David D. Ralph,C. Gregory Elliott,Nicholas S. Hill,David Langleben,Robert Schilz,Vallerie V. McLaughlin,Ivan M. Robbins,Bertron M. Groves,Shelley Shapiro,Thomas A. Medsger,Sean Gaine,Evelyn M. Horn,James C. Decker,Katharine Knobil +29 more
TL;DR: Continuous epoprostenol therapy improves exercise capacity and cardiopulmonary hemodynamics in patients with pulmonary hypertension due to the scleroderma spectrum of disease as discussed by the authors.
Annals of Internal Medicine Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease
David B. Badesch,Victor F. Tapson,Michael D. McGoon,Bruce H. Brundage,Lewis J. Rubin,Fredrick M. Wigley,Stuart Rich,Robyn J. Barst,Pamela S. Barrett,Kenneth M. Kral,James E. Loyd,Srinivas Murali,A. Frost,Reda E. Girgis,Robert C. Bourge,David D. Ralph,C. Gregory Elliott,Nicholas Hill,David Langleben,Robert J. Schilz,Vallerie V. McLaughlin,Ivan M. Robbins,Bertron M. Groves,Shelley M. Shapiro,Sean Gaine,Evelyn M. Horn,James C. Decker,Katharine Knobil +27 more
TL;DR: Results from a single-center, uncontrolled study suggest that long-term, continuously infused epoprostenol therapy can produce hemodynamic and symptomatic responses in patients with connective tissue disease who have severe pulmonary hypertension that is refractory to conventional medical therapy.
No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year.
David B. Allen,Eli O. Meltzer,Robert F. Lemanske,Edward E. Philpot,Melissa A. Faris,Kenneth M. Kral,Barbara A. Prillaman,Kathleen Rickard +7 more
TL;DR: It is demonstrated that fluticasone propionate aqueous nasal spray at the maximum recommended dose of two sprays per nostril once daily was equivalent to vehicle placebo with no effects on growth rate in prepubescent children.
Journal ArticleDOI
Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone
D. Stempel,Ibrahim Raphiou,Kenneth M. Kral,Anne Yeakey,Amanda Emmett,Charlene M. Prazma,Kathleen S. Buaron,Steven Pascoe +7 more
TL;DR: Patients who received salmeterol in a fixed-dose combination with fluticasone did not have a significantly higher risk of serious asthma-related events than did those who received flutic asone alone.
Journal ArticleDOI
Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma
David A. Stempel,Stanley J. Szefler,Søren Pedersen,Robert S. Zeiger,Anne Yeakey,Laurie A. Lee,Andrew H. Liu,Herman Mitchell,Kenneth M. Kral,Ibrahim Raphiou,Barbara A. Prillaman,Kathleen S. Buaron,Suyong Yun Kirby,Steven Pascoe +13 more
TL;DR: In this trial involving children with asthma, salmeterol in a fixed-dose combination with fluticasone was associated with the risk of a serious asthma-related event that was similar to the risk with flutingasone alone.